Published clinical trials of single-agent THAL in MMM
| Authors and reference no. . | No. of patients . | Min . | Max . | Dropout/DM . | Anemia response . | Platelet response . | Spleen response . |
|---|---|---|---|---|---|---|---|
| Elliott et al24 | 15 | 506-150 | 400 | 12 (80%) | 3/15 (20%) | 4/5 (80%) | 1/15 (7%) |
| Barosi et al22 | 21 | 100 | 400 | 19 (91%) | 3/7 (43%) | 2/3 (66.7%) | 4/20 (20%) |
| Canepa et al23 | 10 | 200 | 800 | 0 | 3/10 (30%) | 3/10 (30%) | 3/10 (30%) |
| Pozzato et al25 | 6 | 100 | NR | NR | 3/6 (50%) | NR | 0/6 |
| Piccaluga et al26 | 12 | 100 | 600 | 11/12 (92%) | 3/12 (25%) | 3/12 (25%) | 2/12 (16.7%) |
| Merup et al27 | 15 | 200 | 800 | 6/15 (40%) | 0 | 0 | 0 |
| Authors and reference no. . | No. of patients . | Min . | Max . | Dropout/DM . | Anemia response . | Platelet response . | Spleen response . |
|---|---|---|---|---|---|---|---|
| Elliott et al24 | 15 | 506-150 | 400 | 12 (80%) | 3/15 (20%) | 4/5 (80%) | 1/15 (7%) |
| Barosi et al22 | 21 | 100 | 400 | 19 (91%) | 3/7 (43%) | 2/3 (66.7%) | 4/20 (20%) |
| Canepa et al23 | 10 | 200 | 800 | 0 | 3/10 (30%) | 3/10 (30%) | 3/10 (30%) |
| Pozzato et al25 | 6 | 100 | NR | NR | 3/6 (50%) | NR | 0/6 |
| Piccaluga et al26 | 12 | 100 | 600 | 11/12 (92%) | 3/12 (25%) | 3/12 (25%) | 2/12 (16.7%) |
| Merup et al27 | 15 | 200 | 800 | 6/15 (40%) | 0 | 0 | 0 |
Min indicates minimum THAL dose; Max, maximum THAL dose; Dropout/DM, number (percentage) of patients in the trial with early dropout or necessitating dose modification; NR, not reported.
The 50-mg dose was given only as a dose modification after initial toxicity.